Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY:BDX)

170.86 +0.89 (+0.52%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Biden's New Tariffs On Chinese Imports Are A 'Clear Giveaway' To These Two Tesla Rivals, Jim Cramer Says: 'I Like This Policy'
Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Biden administration's decision to impose substantial tariffs on Chinese... 
Via Benzinga
Topics World Trade
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX... 
Via Benzinga
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024
BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
Curious to know how much these dividend aristocrats could grow in the next year? Here's the answer for several well-known shares. 
Via InvestorPlace
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
Want quality picks and reliable income at a discount? Check out these Dividend Aristocrats trading at 52-week lows. 
Via InvestorPlace
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses and marking a significant milestone for the company. 
Via Benzinga
Topics Intellectual Property
Becton Dickinson Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Preview For Becton, Dickinson
Via Benzinga
Here's How Much You Would Have Made Owning Becton Dickinson Stock In The Last 20 Years
Via Benzinga
Should You Buy Solventum (SOLV) Stock After the 3M Spinoff?
Although 3M shareholders have reason to dump the Solventum spinoff, SOLV stock could be intriguing at the right price. 
Via InvestorPlace
Jim Cramer Says Don't Sell This Beauty Brand, Believes KKR And Blackstone 'Can Make More Money'
On CNBC’s "Mad Money Lightning Round," Jim Cramer sang the praises of Energy Transfer LP (NYSE: ET), which posted better-than-expected earnings 
Via Benzinga
Becton, Dickinson And Co. Dividend Stock Analysis
Becton, Dickinson, and Co. provides a wide range of medical devices and diagnostic products used in hospitals, doctors' offices, research labs, and other settings. 
Via Talk Markets
FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns
BD boosts U.S. production of medical syringes following FDA concerns over Chinese-made syringes. Learn how BD addresses patient care continuity amid ongoing quality probe. 
Via Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... 
Via Talk Markets
Peeling Back The Layers: Exploring Becton Dickinson Through Analyst Insights
Via Benzinga
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
Discover seven robotic surgery stocks primed for growth as the industry evolves. Unveil opportunities in a market set to double by 2033. 
Via InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry. 
Via The Motley Fool
3 Stocks to Buy at 52-Week Lows: March 4 Edition
Sometimes a gem can get tossed in the trash, which is what you will find with these three stocks to buy at 52-week lows. 
Via InvestorPlace
Get Paid While You Wait: 7 Dividend Aristocrats to Buy Now
Worried about an upcoming market correction? These seven Dividend Aristocrats are a safe harbor which offer great income streams. 
Via InvestorPlace
Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects
BD exceeds expectations with Q1 2024 adjusted EPS of $2.68 (vs $2.40 consensus). William Blair maintains a positive outlook, confident in BD's progress towards its 2025. 
Via Benzinga
Earnings Scheduled For February 1, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
Biotech And Medtech Portfolio Notes On A Fed Day
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth. 
Via Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.